Precise adaptive radiotherapy for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must be a type called non-keratinizing nasopharyngeal carcinoma (WHO type II or III).
- Your cancer must be stage I through IVA and must not have spread to distant organs.
- You should be fully active or able to do light work (ECOG score 0 or 1).
- You must not have received any prior treatment for nasopharyngeal cancer (like radiation, chemo, or immunotherapy).
- Your blood counts, liver, and kidney function must be within safe limits as checked by standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy for people with nasopharyngeal cancer, a type of head and neck cancer. The goal is to see if a hypofractionated (fewer, larger doses) approach is safe and effective.
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests whether a lower dose of radiation is just as effective as the standard dose for people with early-stage nasopharyngeal cancer, and aims to reduce side effects while keeping the cancer under control.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.